In the latest session, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $1.25 up 2.46% from its previous closing price of $1.22. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 732589 shares were traded.
Ratios:
For a deeper understanding of Aclaris Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 04 ’24 when Powell Andrew Kenneth William bought 6,000 shares for $1.25 per share. The transaction valued at 7,500 led to the insider holds 28,863 shares of the business.
Powell Andrew Kenneth William bought 8,500 shares of ACRS for $10,455 on Mar 01 ’24. The Director now owns 22,863 shares after completing the transaction at $1.23 per share. On Oct 23 ’23, another insider, Monahan Joseph, who serves as the Chief Scientific Officer of the company, sold 6,000 shares for $5.08 each. As a result, the insider received 30,460 and left with 129,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 86.53M and an Enterprise Value of -32.15M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.84 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at -1.03 whereas that against EBITDA is 0.28.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $11.12, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 1.2174, while the 200-Day Moving Average is calculated to be 4.5469.
Shares Statistics:
For the past three months, ACRS has traded an average of 1.72M shares per day and 793.68k over the past ten days. A total of 70.89M shares are outstanding, with a floating share count of 64.48M. Insiders hold about 9.09% of the company’s shares, while institutions hold 89.18% stake in the company. Shares short for ACRS as of Mar 15, 2024 were 5.12M with a Short Ratio of 2.99, compared to 5.83M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.22% and a Short% of Float of 8.32%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.37, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.08 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.32 and -$1.35 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.82, with 7 analysts recommending between -$0.31 and -$1.49.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.48M, while the lowest revenue estimate was $2.26M, resulting in an average revenue estimate of $5.58M. In the same quarter a year ago, actual revenue was $31.25M, down -82.10% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $6M in the next fiscal year. The high estimate is $7.8M and the low estimate is $2.26M. The average revenue growth estimate for next year is up 7.50% from the average revenue estimate for this year.
